The goal of our study was to validate the therapeutic efficacy of enriching GBM tumor cells in the phase of the cell cycle where they are most vulnerable to radiotherapy, mitosis, using a small molecule inhibitor to the mitotic kinesin, KIF11. This evidence concerns the gene KIF11 and glioblastoma.